<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424697</url>
  </required_header>
  <id_info>
    <org_study_id>CRH104150</org_study_id>
    <nct_id>NCT00424697</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-dummy, Four-way Crossover Design Study to Investigate the Changes of fMRI BOLD Activation Induced by Emotional Activation Paradigms Following Single Doses of GW876008 and Lorazepam (Comparator) in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Data suggests that imaging activity of the brain can measure the effects of anti-anxiety
      drugs. This study will investigate the effect of GW876008 on areas of the brain involved with
      thinking and emotion
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in brain activation elicited by Matching Emotional Face Expression paradigm following single oral doses of GW876008 and lorazepam on day 1, sessions 1-4</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>GW876008 blood levels</measure>
    <time_frame>pre-dose &amp; post-dose, sessions 1-4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical rating scales change after dosing: questionnaires collected</measure>
    <time_frame>pre-dose &amp; up to 6-8 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: 12-lead ECG, vital signs, adverse events, clinical labs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD neuroanatomical structure of the emotional brain neurocircuitry and connectivity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD Signal characteristics and connectivity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD Response in the emotional brain neurocircuitry and occipital cortex.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ETCo2 in mm Hg, to be recorded for the duration of the scan session and be synchronized with the single fMRI procedure timing</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) measurements of sleepiness, alertness, calm, tension, and anxiety performed before dosing (baseline), pre-fMRI session, post-fMRI session and just before leaving the facility.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between the anxiety trait (STAI-trait, test battery for neuroticism or liability for Anxiety Disorders) collected at screening and the various pharmacodynamic parameters measured in the various testing conditions.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GW876008 concentration to determine pharmacokinetic parameters to be collected twice per session,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic (PGx) assessments</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of GW876008 to include Vital signs semi-supine; respiratory rate, pulse oximetry and ECG.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fMRI BOLD ALS signal.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR; beats per minute), to be recorded for the whole duration of the scan session and to be synchronized with the single fMRI procedure timing.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate (RR: inspiration per minute), to be recorded for the duration of scan session and be synchronized with the single fMRI procedure timing. .</measure>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW876008</intervention_name>
    <other_name>placebo</other_name>
    <other_name>lorazepam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females aged 18-50 years, inclusive.

          -  STAI-trait score = or &gt; 40.

          -  STAI-state score &lt;50th percentile of the normal population distribution.

          -  Female subjects of non-childbearing.

          -  Female subjects of childbearing potential must agree to use appropriate contraception.

          -  Healthy subjects, as determined by a responsible physician

          -  Body weight â‰¥ 50 kg (110 lbs), and BMI within the range 19-29.9 kg/m2 inclusive.

          -  Demonstrates no significant evidence of active disease, physical or mental impairment
             when assessed by qualified personnel

          -  Non-smoker (abstinence from smoking for at least 6 months before the start of the
             study).

          -  Normal electrocardiogram.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Read, comprehend, and write English at a sufficient level to complete study-related
             materials.

          -  Provide a signed and dated written informed consent prior to study participation

        Exclusion Criteria:

          -  As a result of any of the medical interview, physical examination, evaluation of
             mental state and psychiatric history or screening investigations the physician
             responsible considers the subject unfit for the study.

          -  Any history of suicidal attempts or behaviour.

          -  Any history or current diagnosis of a psychiatric illness.

          -  Any history of an endocrine disorder including, but not limited to, diabetes or
             disorders of the hypothalamus, pituitary, adrenal, or thyroid glands, or gonadal
             disorder or dysfunction of the reproductive organs.

          -  Abnormal pepsinogen I level at screening.

          -  Liver Function Tests (LFTs) elevated above the reference range at pre-study screening
             that remain elevated with a repeat LFT

          -  Any other clinically significant laboratory abnormality.

          -  Positive faecal occult blood test.

          -  Positive pre-study urine drug/alcohol breath screen.

          -  Positive pre-study HIV 1/2, Hepatitis B surface antigen and positive Hepatitis C
             antibody result within 3 months of the start of the study.

          -  Pre-existing or current Helicobactor pylori infection.

          -  History of alcohol/drug abuse or dependence within 12 months of the study

          -  Consumption of grapefruit juice or grapefruit within 14 days prior to the first dose
             of study medication.

          -  History of peptic ulcer disease.

          -  Abnormal screening ECG

          -  History of long QT syndrome (personal or family) or other cardiac conduction disorder,
             or other clinically significant cardiac disease.

          -  Systolic blood pressure &lt; 90mmHg or &gt;140mmHg; diastolic blood pressure &lt; 60mmHg or &gt;
             90mmHg; pulse rate &lt; 40bpm or &gt; 90bpm.

          -  Participation in a clinical trial with a drug or new chemical entity within 30 days or
             5 half-lives, or twice the duration of the biological effect of any drug (whichever is
             longer) prior to the first dose of current study medication.

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the physician responsible,
             contraindicates their participation.

          -  History or current diagnosis of acute narrow angle glaucoma.

          -  Where participation in study would result in donation of blood in excess of 500 mL
             within a 56 day period.

          -  Current or recent (within one year) gastrointestinal disease; a history of
             malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a
             week) occurrence of heartburn; or any surgical intervention (e.g., cholecystectomy)
             which would be expected to influence the absorption of drugs.

          -  Average daily caffeine intake equivalent to &gt; 4 cups of coffee or &gt; 6 cups of tea.

          -  Subjects who are left handed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MBChB, MFPM</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2007</study_first_posted>
  <disposition_first_submitted>October 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 15, 2010</disposition_first_posted>
  <last_update_submitted>October 13, 2010</last_update_submitted>
  <last_update_submitted_qc>October 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Brain imaging,</keyword>
  <keyword>fMRI,</keyword>
  <keyword>stimulation,</keyword>
  <keyword>pharmacodynamics,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

